Xenon Pharmaceuticals Inc.

Abbvie Inc.

Pramana Pharmaceuticals Inc.

Qlt Inc.

Dermira (canada), Inc.

Kinetek Pharmaceuticals, Inc.

Valocor Therapeutics, Inc.

Mikhail A Chafeev

Sultan Chowdhury

Jianmin Fu

Serguei Sviridov

Shaoyi Sun

Shifeng Liu

Jean-Jacques Alexandre Cadieux

Nagasree Chakka

Jianyu Sun

Zaihui Zhang

Qi Jia

Rajender Kamboj

Alla Yurevna Zenova

Duanjie Hou

Vandna Raina

Mark Wood

Jonathan David Langille

Simon James Gauthier

Timothy Scott Daynard

Shisen Wang

Mehran Seid Bagherzadeh

Anil Vasudevan

Vishnumurthy Kodumuru

Jian-Min Fu

Melwyn A Abreo

Mark W Holladay

Michael D Winther

Heinz W Gschwend

Chi Tu

Wenbao Li

Gregory B Chopiuk

Arthur Gomtsyan

Kristine E Frank

Tarek Suhayl Mansour

Tami J Pilot-Matias

Michael M Friedman

Kathy A Sarris

Daniel F Harvey

Tom Hsieh

Robert Fraser

Lauren Fraser

Elke Huthmann

Thomas Isarno

Amy Frances Douglas

Zoran Cikojevic

Stefanie Abel

Emad El-Sayed

Sengen Sun

Tatyana Dekhtyar

Iok Chan Ng

M-akhteruzzaman Molla

Artour Gomtsian

Mehran Bagherzadeh

Mikhail Kondratenko

Nathan Josephsohn

Cindy J Hudson

Kashinath Sadalapure

Renata Marcella Oballa

Mikhail Yudin

Ana Aguirre

Yury Gezentsvey

Aleksandr Nikitin

Qi Ji

Mikhail A Kondratenko

Jian-min Fu

Timothy S Daynard

Greg B Chopiuk

Serguei V Sviridov

Kashinath Sadalupure

Sun Shaoyi

Michael Winther

Heinz Gschwend

There are provided compounds having formula (I), in which: Xand Xare selected from certain combinations of O, S, SO and SO; Xis selected from CH, CF and N; Xis selected from CH and N; X, Xand Xare selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; Xand Xare selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both Xand Xtogether form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I) 

Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119

There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.

Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Thiazoles and uses thereof

This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Substituted cyanoguanidines as oral anti-virals

This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Synthetic methods for spiro-oxindole compounds

This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.

Benzenesulfonamide compounds and their use as therapeutic agents

This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.

Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Diaminopyrimidines and uses thereof

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Growing community of inventors

Vancouver, Canada

Mikhail A Chafeev